Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 17;13(2):322.
doi: 10.3390/cancers13020322.

The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance

Affiliations
Review

The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance

Javier Martinez-Useros et al. Cancers (Basel). .

Abstract

In the last decade, several studies based on whole transcriptomic and genomic analyses of pancreatic tumors and their stroma have come to light to supplement histopathological stratification of pancreatic cancers with a molecular point-of-view. Three main molecular studies: Collisson et al. 2011, Moffitt et al. 2015 and Bailey et al. 2016 have found specific gene signatures, which identify different molecular subtypes of pancreatic cancer and provide a comprehensive stratification for both a personalized treatment or to identify potential druggable targets. However, the routine clinical management of pancreatic cancer does not consider a broad molecular analysis of each patient, due probably to the lack of target therapies for this tumor. Therefore, the current treatment decision is taken based on patients´ clinicopathological features and performance status. Histopathological evaluation of tumor samples could reveal many other attributes not only from tumor cells but also from their microenvironment specially about the presence of pancreatic stellate cells, regulatory T cells, tumor-associated macrophages, myeloid derived suppressor cells and extracellular matrix structure. In the present article, we revise the four molecular subtypes proposed by Bailey et al. and associate each subtype with other reported molecular subtypes. Moreover, we provide for each subtype a potential description of the tumor microenvironment that may influence treatment response according to the gene expression profile, the mutational landscape and their associated histology.

Keywords: chemotherapy response; microenvironment; molecular subtypes of pancreatic cancer; myeloid derived suppressor cells; pancreatic stellate cells; regulatory T cells; tumor-associated macrophages.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Squamous molecular profile and microenvironment. (a) Squamous subtype is associated with specific histological characteristics such as squamous and adenosquamous carcinomas. (b) Squamous subtype proposed by Bailey et al., matches perfectly with "quasi-mesenchymal" tumor subtype proposed by Collisson et al., and “basal-like” tumors and “activated” stroma subtypes proposed by Moffitt et al. Green boxes contain upregulated significant factors and activated pathways associated to squamous molecular subtype. Red boxes contain downregulated significant factors (up) and most common mutations found in squamous molecular subtype (down). Percentage of each subcellular population has been obtained from Peng et al., [86]. Abbreviations: TAM: Tumor-associated macrophage; CAF: Cancer-associated fibroblast; PSC: Pancreatic stellate cell.
Figure 2
Figure 2
Immunogenic and progenitor molecular profiles and their microenvironment. (a) Both subtypes proposed by Bailey et al., match perfectly with “classical” tumor subtype proposed by Collisson et al., and “classical” tumor subtype proposed by Moffitt et al. (b) Both subtypes share the same histology derived from premalignant lesions like mucinous non-cystic adenocarcinomas and intraductal papillary mucinous neoplasms (IPMN) characterized by high mucin production. Dotted line separates schematic representation of two subtypes. Green boxes contain upregulated significant factors associated to each subtype. Red box contains the most characteristic gene mutation in progenitor molecular subtype. Pink color represents mucin production. Percentage of each subcellular population has been obtained from Peng et al., [86]. Abbreviations: TAM: tumor-associated macrophage; CAF: cancer-associated fibroblast; PSC: pancreatic stellate cell.4. Microenvironment of ADEX Subtype.
Figure 3
Figure 3
ADEX molecular profile and microenvironment. (a) ADEX subtype proposed by Bailey et al., matches perfectly with “exocrine-like” subtype proposed by Collisson et al., and most of “normal stroma” subtype cases analyzed by Moffitt et al. (b) ADEX molecular subtype is associated with the rare acinar histology. Green boxes contain upregulated transcription factors and other genes involved in ADEX molecular subtype. Red box contains genes commonly mutated in ADEX. Percentage of each subcellular population has been obtained from Peng et al., [86]. Abbreviations: TAM: tumor-associated macrophage; CAF: cancer-associated fibroblast; PSC: pancreatic stellate cell; MODY: maturity onset diabetes of the young.

References

    1. Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res. 2014;74:2913–2921. doi: 10.1158/0008-5472.CAN-14-0155. - DOI - PubMed
    1. Tamm E.P., Bhosale P.R., Vikram R., de Almeida Marcal L.P., Balachandran A. Imaging of Pancreatic Ductal Adenocarcinoma: State of the Art. World J. Radiol. 2013;5:98–105. doi: 10.4329/wjr.v5.i3.98. - DOI - PMC - PubMed
    1. Kelsen D.P., Portenoy R., Thaler H., Tao Y., Brennan M. Pain as a Predictor of Outcome in Patients with Operable Pancreatic Carcinoma. Surgery. 1997;122:53–59. doi: 10.1016/S0039-6060(97)90264-6. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2019. CA Cancer J. Clin. 2019;69:7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. Duffy M.J., Sturgeon C., Lamerz R., Haglund C., Holubec V.L., Klapdor R., Nicolini A., Topolcan O., Heinemann V. Tumor Markers in Pancreatic Cancer: A European Group on Tumor Markers (EGTM) Status Report. Ann. Oncol. 2010;21:441–447. doi: 10.1093/annonc/mdp332. - DOI - PubMed

LinkOut - more resources